Vosoritide Treatment Guide: Voxzogo, Cost and Provider Paths
In the United States, Vosoritide is an FDA-approved peptide therapy. Achondroplasia in children aged 5 years and older with open epiphyses (growth plates)
This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.
Vosoritide is a recombinant analog of C-type natriuretic peptide (CNP) approved by the FDA for achondroplasia in children aged 5 years and older with open growth plates. It is the first and only disease-modifying therapy for the most common form of dwarfism.
Approved Product Paths
Branded vosoritide pathway. Achondroplasia in children aged 5 years and older with open epiphyses (growth plates)
- •First disease-modifying therapy for achondroplasia
- •Significantly increases annual growth velocity in children
- •Improves body proportions over time
- •Once-daily subcutaneous injection (home administration)
- •Injection site reactions (erythema, swelling, pain)
- •Vomiting
- •Transient decrease in blood pressure (due to natriuretic peptide vasodilation)
- •Headache
How Vosoritide Works
Vosoritide is a recombinant 39-amino-acid C-type natriuretic peptide (CNP) analog. It binds to natriuretic peptide receptor B (NPR-B) on growth plate chondrocytes, stimulating endochondral bone growth in children with achondroplasia.
Vosoritide is a CNP analog designed to target the FGFR3 signaling pathway in achondroplasia. In achondroplasia, activating mutations in fibroblast growth factor receptor 3 (FGFR3) inhibit chondrocyte proliferation and differentiation in the growth plate.
CNP normally signals through NPR-B receptors on growth plate chondrocytes, activating the MAPK pathway and counteracting the inhibitory effects of FGFR3. Vosoritide amplifies this natural signaling pathway.
By increasing CNP signaling, vosoritide promotes chondrocyte proliferation, hypertrophy, and matrix production in the growth plate. This accelerates endochondral ossification and increases linear growth velocity.
Vosoritide does not alter the underlying FGFR3 mutation. It works downstream to overcome the signaling defect, making it a pathway-targeted therapy rather than a genetic cure.
The drug is administered as a daily subcutaneous injection. Growth velocity improvement is typically seen within 6 months, with continued benefit as long as growth plates remain open.
Vosoritide is the first FDA-approved therapy specifically for achondroplasia, representing a milestone in precision treatment for genetic skeletal dysplasias.
Clinical Trial Evidence
Phase 3 trial
PMID: 32937083- Mean increase in growth velocity: 1.57 cm/year vs 0.02 cm/year placebo (p<0.0001)
- Height Z-score improved by 0.3
- Proportionate growth maintained (no disproportionate limb/trunk ratio change)
- Well tolerated with mild injection site reactions
Dosing & Administration
- •Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites
- •Administer at same time each day
- •Take with or without food
- •Reconstitute with provided diluent
- •Use immediately after reconstitution or within 2 hours if refrigerated
Side Effect Profile
Very common
Erythema, swelling, pain; usually mild and transient
Usually mild
Common
Mild
Mild
Transient hypotension; usually asymptomatic
Mild
Serious
CNP has vasodilatory effects; usually mild and brief
Contraindications & Warnings
Do Not Use
- Closed growth plates (drug will not work after epiphyseal fusion)
- Pregnancy
- Known hypersensitivity to vosoritide
Important Warnings
- Hypotension: transient blood pressure decrease may occur, particularly after dose changes. Monitor BP at visits.
- Closed growth plates: drug is ineffective after epiphyseal fusion. Monitor bone age periodically.
- Not a cure for achondroplasia: improves growth velocity but does not correct underlying FGFR3 mutation.
- Long-term effects on final adult height and body proportions still being studied.
- No data on use in children under 5 years or over 14 years.
Drug Interactions
| Drug | Interaction | Severity | Mechanism |
|---|---|---|---|
| None significant | Minimal interaction potential | minor | Peptide metabolized by proteolysis; not CYP-dependent |
Monitoring Requirements
- Height and growth velocity every 3-6 months
- Bone age annually (to assess remaining growth potential)
- Blood pressure at visits
- Body proportions (limb/trunk ratios)
- Injection site reactions
- Weight for dose calculation
How Vosoritide Compares
Significant improvement in linear growth
GH does not work well in achondroplasia; vosoritide addresses specific molecular defect
Medical therapy far less invasive than surgical lengthening
Evidence Quality Assessment
Is Vosoritide Right for You?
Ideal Candidates
- Children with achondroplasia ages 5-14 years with open growth plates
- Families seeking medical intervention to improve linear growth
- Patients with sufficient growth remaining to benefit (bone age assessment important)
Avoid
- Children with closed or nearly closed growth plates
- Age <5 years (not studied)
- Families with unrealistic expectations (drug improves growth but does not normalize height)
Use With Caution
- Children with cardiovascular disease
- Those with significant injection anxiety
- Patients nearing puberty (less growth potential remaining)
Cost & Insurance Deep Dive
Savings Programs
Cost-Effectiveness Notes
- •Extremely high cost for ultra-rare indication
- •Annual cost may exceed $350,000
- •Cost per centimeter of height gain is very high
- •Value depends heavily on family priorities and access to insurance
Ready to find a vosoritide provider?
Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.
Find a vosoritide providerProgress Tracking Tools
Monitor health markers and outcomes during treatment.
Smart WiFi Body Scale
Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.
Digital Kitchen Food Scale
Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.
Protein Shaker Bottle Set
Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Vosoritide FAQ
Sources
- 1. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.N Engl J Med • 2019Claim type: clinicalView source →
- 2. FDA Information on VosoritideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.